Neonc Technologies Holdings, Inc. (NTHI) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Calabasas, CA, United States. El CEO actual es Amir Farrokh Heshmatpour.
NTHI tiene fecha de IPO 2025-03-26, 8 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $103.17M.
Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
